Ursprung des Netzwerks ersten Grades von Ajay Duggal
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 6 | |
Xenothera SAS
 Xenothera SAS BiotechnologyHealth Technology Xenothera SAS is a biotechnologies company. It creates therapeutic modes in numerous domains from immunomodulation to infectious diseases. The company was founded on June 30, 2014 and is headquartered in
3
| Holding Company | Biotechnology | 3 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Ajay Duggal
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| THE SUSTAINABLE NUTRITION GROUP LTD | Agricultural Commodities/Milling | Chief Executive Officer | |
| OSE IMMUNOTHERAPEUTICS | Pharmaceuticals: Major | Chief Operating Officer | |
Hangzhou Adlai Nortye Biopharma Co. Ltd.
 Hangzhou Adlai Nortye Biopharma Co. Ltd. BiotechnologyHealth Technology Part of Adlai Nortye Ltd., Hangzhou Adlai Nortye Biopharma Co. Ltd. is a clinical-stage biopharmaceutical company based in Hangzhou, China. Adlai Nortye is developing differentiated, innovative immuno-oncology medicines with a focus on discovering and developing important new treatments for cancer. The Chinese company's mission is to improve patient lives by identifying and developing differentiated innovative medicines that help people live better and longer. The company was founded in 2004 by Yang Lu, Dong Hui Yang, and Yang Lu has been the CEO since then. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
HaemaLogiX Pty Ltd.
 HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | Biotechnology | Chief Executive Officer | |
| The University of Sydney | College/University | Graduate Degree | |
| Macquarie University | College/University | Graduate Degree | |
| The University of New South Wales | College/University | Undergraduate Degree | |
| PHARMING GROUP N.V. | Pharmaceuticals: Major | Sales & Marketing | |
| University of New South Wales Built Environment | College/University | Doctorate Degree | |
| SIMBLE SOLUTIONS LIMITED | Packaged Software | Director/Board Member | |
| Nucleics Ltd. | Chief Executive Officer | ||
| School of Biotechnology & Biomolecular Sciences | College/University | Doctorate Degree | |
| Université Catholique de Louvain | College/University | Doctorate Degree | |
Institut National de la Santé & de la Recherche Médicale
 Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Centre National de la Recherche Scientifique
 Centre National de la Recherche Scientifique General GovernmentGovernment Centre National de la Recherche Scientifique provides scientific research services. The firm engages in the research capable of advancing knowledge and bringing social, cultural, and economic benefits for society. The company was founded in 1939 and is headquartered in Paris, France. | General Government | Corporate Officer/Principal | |
| ZENYTH THERAPEUTICS LIMITED | Pharmaceuticals: Major | Chief Executive Officer | |
| IMPEDIMED LIMITED | Medical Specialties | Director/Board Member | |
Canaccord Genuity (Australia) Ltd.
 Canaccord Genuity (Australia) Ltd. Investment Banks/BrokersFinance Canaccord Genuity (Australia) Ltd. (Canaccord Genuity Australia) is the Australian full service stockbroking and wealth management subsidiary of Canaccord Genuity Group Inc. (TSE: CF) in Canada. Headquartered in Melbourne, Canaccord Genuity Australia was founded by Anthony Murphy and provides wealth management services including portfolio management, portfolio administration and broking services to individual, institutional and corporate clients. | Investment Banks/Brokers | Director/Board Member | |
Monash University
 Monash University Other Consumer ServicesConsumer Services Monash University operates as a public research university. It specializes in higher education, global engagement, postgraduate courses, undergraduate study, and PhD research. The company was founded on March 1961 and is headquartered in Clayton, Australia. | College/University | Graduate Degree | |
| BOTANIX PHARMACEUTICALS LIMITED | Pharmaceuticals: Major | Director/Board Member | |
| ALCIDION GROUP LIMITED | Packaged Software | Director/Board Member | |
Shaw & Partners Corporate Finance Pty Ltd.
 Shaw & Partners Corporate Finance Pty Ltd. Investment Banks/BrokersFinance Part of EFG International AG, Shaw & Partners Corporate Finance Pty Ltd. is a brokerage firm founded in 1987. The company is based in Sydney, Australia and provides brokerage services. | Investment Banks/Brokers | Corporate Officer/Principal | |
MycRx
 MycRx Miscellaneous Commercial ServicesCommercial Services MycRx is an Australian company that focuses on improving the lives of people with cancer through direct myc inhibitors. The company's main area of expertise is the science of myc inhibition as a treatment for cancer. | Miscellaneous Commercial Services | Director/Board Member | |
| Myrio Therapeutics Pty Ltd. | Chief Executive Officer | ||
Ascend Biopharmaceuticals Ltd.
 Ascend Biopharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Ascend Biopharmaceuticals Ltd. is a cancer immunotherapy company that develops medicines to treat primary, recurrent, and metastatic cancers. It offers pipeline strategy that focuses on a number of oncology and dermato-oncology settings. The company was founded by Clement Leong on September 10, 2003 and is headquartered in Melbourne, Australia. | Pharmaceuticals: Major | Chairman | |
| University of Cambridge | College/University | Doctorate Degree | |
Cerylid Biosciences Ltd.
 Cerylid Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Cerylid Biosciences Ltd. is an Australian pharmaceutical company that manufactures pharmaceutical products. The private company is based in Richmond, Australia. | Pharmaceuticals: Major | Chief Executive Officer | |
| Kyowa Kirin, Inc. | Chief Tech/Sci/R&D Officer |
Statistik
International
| Australien | 20 |
| Frankreich | 5 |
| Vereinigtes Königreich | 4 |
| Vereinigte Staaten | 3 |
| China | 2 |
Sektoral
| Health Technology | 13 |
| Consumer Services | 9 |
| Commercial Services | 4 |
| Technology Services | 3 |
| Finance | 3 |
Operativ
| Director/Board Member | 14 |
| Chief Executive Officer | 11 |
| Chief Tech/Sci/R&D Officer | 6 |
| Corporate Officer/Principal | 5 |
| Founder | 4 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Peter Smith | 10 |
| Daniel Sharp | 7 |
| Bernard Vanhove | 6 |
| Damian Clarke-Bruce | 6 |
| Daniel Tillett | 5 |
| Michelle Rashford | 3 |
| Tim Hammond | 2 |
| Odile Duvaux | 1 |
| Cesare Galli | 1 |
- Börse
- Insiders
- Ajay Duggal
- Unternehmensverbindungen
